Curia, formerly AMRI, a contract research, development and manufacturing organization, announced plans to expand its commercial manufacturing capacity at its Rensselaer, NY facility. The increased capability to flexibly manufacture complex active pharmaceutical ingredients (APIs) will further strengthen Curia’s ability to partner with customers, meeting small-scale to large-volume requirements with reliable delivery.   Curia is investing approximately $35 million in these state-of-the-art expand...